Conventional transbronchial biopsy with forceps often yields small specimens with crush artifact, limiting diagnostic accuracy for pulmonary lesions. Recent clinical trials indicate that cryoprobe biopsy provides larger, more intact specimens, leading to a higher diagnostic yield for various thoracic pathologies.
Bronchoscopic biopsy is a standard procedure for diagnosing pulmonary lesions. However, the conventional method using forceps can result in small specimen sizes and poor specimen quality due to crush artifact, which may compromise diagnostic accuracy.1,2,3 This limitation necessitates alternative approaches to improve tissue acquisition.
The FROSTBITE-2 Randomized Clinical Trial and Related Studies
The FROSTBITE-2 Randomized Clinical Trial, published in JAMA in 2026, investigated the efficacy of cryobiopsy versus forceps for bronchoscopic lung biopsy. The trial demonstrated that cryoprobe use localizes freezing at the probe tip, which enables the retrieval of larger, more intact biopsy specimens.1 This mechanism directly addresses the limitations observed with forceps, where crush artifact frequently degrades specimen quality.1
Further research supports these findings. A 2025 study in the Journal of Visualized Experiments examined the application value and safety of ultrafine bronchoscopy combined with frozen lung biopsy in the diagnosis of peripheral pulmonary nodules. This study similarly concluded that cryoprobe use localizes freezing at the probe tip, facilitating the retrieval of larger, more intact biopsy specimens compared to conventional forceps.2 The improved specimen quality is critical for accurate histological assessment, particularly in cases of subtle or early-stage lesions.
Another prospective observational study, published in Annals of Medicine in 2025, compared sequential cryoprobe and biopsy forceps in endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal and hilar lesions. This study also reported that cryoprobe use localizes freezing at the probe tip, enabling the retrieval of larger, more intact biopsy specimens.3 The consistency across these studies highlights a clear advantage of cryoprobe technology in obtaining diagnostic tissue.
The primary benefit of cryoprobe technology lies in its ability to preserve tissue architecture. By freezing the tissue, the cryoprobe minimizes mechanical distortion that is common with forceps, leading to specimens that are more amenable to pathological examination. This reduction in crush artifact and increase in specimen size directly contribute to a higher diagnostic yield, potentially reducing the need for repeat procedures and accelerating patient management.1,2,3
The consistent evidence from trials like FROSTBITE-2 and other observational studies points towards a clear advantage for cryoprobe technology in transbronchial biopsy. For clinicians, this means a higher likelihood of obtaining a definitive diagnosis from the initial procedure, potentially reducing patient discomfort from repeat biopsies and accelerating the time to treatment initiation. The improved specimen quality, free from crush artifact, will undoubtedly be welcomed by pathologists, allowing for more confident and precise diagnoses, especially in complex cases where subtle cellular features are critical.
From an industry perspective, the adoption of cryoprobe technology represents a significant shift in the market for bronchoscopic biopsy tools. Manufacturers of conventional forceps may see a decline in demand as healthcare systems invest in cryoprobe systems. This could also drive innovation in cryoprobe design, focusing on miniaturization, ease of use, and integration with existing bronchoscopy platforms. Training programs for pulmonologists and interventional radiologists will need to adapt to incorporate the specific techniques and safety considerations associated with cryobiopsy.
For patients, the implications are substantial. A higher diagnostic yield translates to fewer invasive procedures, less anxiety, and a quicker path to appropriate therapy. In an era where early diagnosis is paramount for conditions like lung cancer, any technology that improves the efficiency and accuracy of tissue acquisition is a net positive. While the initial investment in cryoprobe equipment may be higher, the long-term benefits of reduced repeat procedures and improved patient outcomes could justify the cost, making it a valuable addition to the diagnostic armamentarium.
- The Pivot Cryoprobe biopsy offers superior specimen quality and diagnostic yield compared to traditional forceps biopsy.
- The Data Cryoprobe use localizes freezing at the probe tip, enabling retrieval of larger, more intact biopsy specimens.
- The Action Clinicians performing bronchoscopic lung biopsies should consider cryoprobe technology to enhance diagnostic success.
ART-2026-462
06/26
Cite This Article
Team TLSFE. Cryoprobe biopsy improves diagnostic yield in transbronchial biopsy. The Life Science Feed. Updated June 21, 2026. Accessed June 21, 2026. https://thelifesciencefeed.com/pulmonology/pneumonia/research/cryoprobe-biopsy-improves-diagnostic-yield-in-transbronchial-biopsy.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Medical Disclaimer
The information provided on The Life Science Feed is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider regarding any medical condition or treatment decision. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
References
1. Thiboutot J, Kapp CM, Illei P. Cryobiopsy vs Forceps for Bronchoscopic Lung Biopsy: The FROSTBITE-2 Randomized Clinical Trial. JAMA. 2026.
2. Tian A, Wu X, Liang Y. The Application Value and Safety of Ultrafine Bronchoscopy Combined with Frozen Lung Biopsy in the Diagnosis of Peripheral Pulmonary Nodules. J Vis Exp. 2025.
3. Lin CK, Ruan SY, Fan HJ. Comparison of sequential cryoprobe and biopsy forceps in endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal and hilar lesions: a prospective observational study. Ann Med. 2025.
